Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
SecuraBio
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
≥ 18 years of age;
Progressed during, refractory to, intolerant of, or ineligible for established therapy, or has a disease with no established therapy with the exception of expansion cohort of treatment naïve CLL patients;
An Eastern Cooperative Oncology Group (ECOG) score of 0 to 2.
You may not be if
Any previous treatment with a PI3K inhibitor (Escalation Phase only) or within 4 weeks of the start of IPI-145 administration (Expansion Phase);
Patients with overt leptomeningeal leukemia or CNS lymphoma;
Inadequate hepatic function defined by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 2.5 x upper limit of normal (ULN); direct bilirubin \>1.5 x ULN;
Inadequate renal function defined by serum creatinine \> 1.5 x ULN
Clareo Health | A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
